Top Story

FDA requests data on daclatasvir in combination with other agents

November 26, 2014

The FDA issued a complete response letter to Bristol-Myers Squibb in response to its new drug application for daclatasvir, an NS5A complex inhibitor.

The FDA is requesting additional data for the drug’s treatment of hepatitis C virus in combination with other antiviral agents, as the original new drug application focused on a daclatasvir-asunaprevir combination. Bristol-Myers Squibb withdrew the new drug application for asunaprevir, an NS3/4A protease inhibitor, in October.

Thomas Frieden Perspective

CDC: 30% of people with HIV achieved viral suppression

November 26, 2014
Of the approximately 1.2 million Americans with HIV, just 30% achieved viral suppression in 2011, according to November’s Vital Signs report in MMWR. Data from…
Meeting News Coverage

Post-transplant sofosbuvir/simeprevir regimen effective, well tolerated

November 26, 2014
BOSTON — An all-oral antiviral regimen of sofosbuvir and simeprevir was associated with high sustained virologic response regardless of the addition of ribavirin…
In the Journals

Restroom hand dryers spread more bacteria than paper towels

November 26, 2014
The use of air-powered hand dryers may spread more airborne bacteria than paper towels, according to data published in the Journal of Hospital Infection. Researchers…
Meeting News Coverage

Risky behavior, crowded settings increased risk for college campus outbreaks

November 26, 2014
NEW YORK — Crowded environments, increased risky behavior and diverse populations typical within the college setting were associated with increased risk for…
More News Headlines »
CME
HCV Consults: Volume 1, Number 3

HCV Consults: Volume 1, Number 3

This activity is supported by educational grants from AbbVie and Genentech, Inc.

More »
Meeting News Coverage Video
IGRA TB tests expected to significantly reduce false-positive results compared with TST

IGRA TB tests expected to significantly reduce false-positive results compared with TST

November 23, 2014
NEW YORK — Jeffrey R. Starke, MD, an Infectious Diseases in Children Editorial Board member, addresses the…
More »
CME
j526

Regimen Selection in HIV: Considering New Options to Optimize Outcomes

This activity is supported by an educational grant from Gilead Sciences Medical Affairs.

More than two decades into the antiretroviral therapy (ART) era, there are numerous options for HIV treatment. The goal…
More »
morganatic-roan